Key Takeaways

  • SightGlass Vision says 2 million children worldwide have now worn Dot spectacle lenses, doubling the reported number of wearers in less than a year
  • In the Cathay study, Dot lenses reduced mean myopia progression by 67% and mean axial length progression by 62% after 2 years versus control among Chinese children aged 6 to 13 years
  • The spectacle lenses use Diffusion Optics Technology to manage retinal contrast as an approach to slowing childhood myopia progression

SightGlass Vision announced that 2 million children worldwide have now worn its Dot spectacle lenses for myopia control, reaching the milestone less than a year after the company surpassed 1 million wearers.

According to SightGlass, the milestone reflects growing adoption of spectacle-based approaches to childhood myopia management. Dot lenses use the company’s Diffusion Optics Technology, an approach designed to manage retinal contrast while providing vision correction.

“Two million children in Dot lenses is a powerful reminder of why we do this work, and a testament to the need for this safe and effective myopia control treatment,” Andrew Sedgwick, CEO of SightGlass Vision, said in a company statement. “We’re proud that so many eye care professionals trust Dot lenses to correct their young patients’ vision today and help reduce future eye health risks.”

SightGlass Vision also highlighted recent clinical findings from its Cathay study in China. According to the company, Dot lenses slowed mean myopia progression by 67%, corresponding to 0.78 D, and mean axial length progression by 62%, or 0.40 mm, after 2 years compared with the control group among Chinese children aged 6 to 13 years.

Among children aged 6 to 10 years, the company reported that treatment with the lenses resulted in more than 1 D less myopia progression on average after 2 years.

The technology is based on research investigating the relationship between retinal contrast and eye growth. Dot lenses incorporate thousands of microscopic elements that softly scatter light before it reaches the retina, with the aim of reducing contrast while maintaining a clear central zone for vision.

“Parents are often surprised to learn how quickly myopia can progress in young children,” said Craig McArthur of Peter Ivins Eye Care in the United Kingdom. “Dot lenses fill the need for an easy and highly effective solution to offer families, and having strong clinical evidence behind that recommendation gives us greater confidence in those conversations with parents.”

SightGlass Vision has also introduced its Control the Contrast professional education campaign, which is intended to help eye care professionals understand the science underlying contrast management and its application to myopia care.

Dot lenses first became commercially available in 2021 and have since launched in Canada, China, Israel, Spain, and the United Kingdom. SightGlass Vision said additional market introductions are anticipated in 2026.

Founded in 2016, SightGlass Vision operates as a joint venture between CooperVision and Essilor International.